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ABSTRACT 
Background: The tradeoff in safety vs. efficacy in substituting a non-vitamin K antagonist oral 
anticoagulant (NOAC) for a vitamin K antagonist (VKA) in the stented atrial fibrillation (AF) 
patient has not been quantitatively evaluated. Methods: Based upon summary data from the 
PIONEER AF-PCI and RE-DUAL PCI trials, 4 antithrombotic regimens were compared with 
VKA-based triple therapy: (1) rivaroxaban (riva) 15 mg daily + P2Y12 inhibitor; (2) riva 2.5 mg 
twice daily + P2Y12 inhibitor + aspirin; (3) dabigatran (dabi) 110 mg twice daily + P2Y12 
inhibitor; and (4) dabi 150 mg twice daily + P2Y12 inhibitor. A bivariate model with a non-
inferiority margin of 1.38 was used to simultaneously assess safety and efficacy. The safety 
endpoint was major or clinically relevant nonmajor bleeding by International Society on 
Thrombosis and Haemostasis definitions. The efficacy endpoint was a thromboembolic event 
(myocardial infarction, stroke, or systemic embolism), death, or urgent revascularization. The 
bivariate outcome, a measure of risk difference in the net clinical outcome, was compared 
between antithrombotic regimens. Results: All 4 NOAC regimens were superior in bleeding and 
non-inferior in efficacy compared with triple therapy with VKA. Riva 15 mg daily and 2.5 mg 
twice daily were associated with bivariate combined risk reductions of 5.6% (2.3%–8.8%) and 
5.5% (2.1%–8.7%) respectively, and dabi 110 mg twice daily and 150 mg twice daily reduced 
the bivariate risk by 3.8% (0.5%–7.0%) and 6.3% (2.4%–9.8%) respectively. Conclusions: A 
bivariate analysis that simultaneously characterizes both risk and benefit demonstrates that 
rivaroxaban- and dabigatran-based regimens were both favorable over VKA plus dual 
antiplatelet therapy among patients with AF undergoing PCI. 
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Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: 
NCT01830543 (PIONEER AF-PCI); NCT02164864 (RE-DUAL PCI) 
 
Keywords: thromboembolism; myocardial infarction; stroke; revascularization; mortality; 
bleeding; anticoagulant 
 
Abbreviations: 
AF, atrial fibrillation 
ISTH, International Society on Thrombosis and Haemostasis 
NCB, net clinical benefit 
NOAC, non-vitamin K antagonist oral anticoagulant 
PCI, percutaneous coronary intervention 
TIMI, Thrombolysis in Myocardial Infarction 
VKA, vitamin K antagonist 
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INTRODUCTION 
 Approximately 3 to 10% of patients scheduled for percutaneous coronary intervention 
(PCI) with stent implantation have atrial fibrillation (AF) and both anticoagulant and antiplatelet 
therapy are indicated to prevent thromboembolic or coronary events.
1, 2
  Current practice 
guidelines recommend anticoagulation with a vitamin K antagonist (VKA) plus dual antiplatelet 
therapy with a P2Y12 inhibitor and aspirin as the standard-of-care in this setting.
3-7
  However, 
VKA-based triple therapy has been associated with a greater risk of major hemorrhage,
8, 9
 and 
this risk of bleeding has prompted efforts to develop new antithrombotic strategies.  Until 
recently, two randomized controlled trials (PIONEER AF-PCI
10
 and RE-DUAL PCI
11
) compared 
the safety and efficacy of non-vitamin K antagonist oral anticoagulant (NOAC) to triple therapy 
and demonstrated significant bleeding reduction with comparable ischemic outcomes.  However, 
the simultaneous tradeoff between bleeding and ischemic outcomes has not been quantitatively 
evaluated. 
 The present study aims to compare the risk-benefit profile of NOAC-based 
antithrombotic regimens versus VKA-based triple therapy based upon the results of PIONEER 
AF-PCI trial and RE-DUAL PCI trial.  We applied a previously developed bivariate analysis 
approach
12
 to assess the net clinical benefit of therapy that simultaneously weighs 
thromboembolism, death, and urgent revascularization against bleeding risks.
13
 
 
METHODS 
Data Extraction and Study Endpoints 
 Two randomized controlled trials that compared NOAC-based anticoagulation with VKA 
in AF patients undergoing coronary stenting were included: PIONEER AF-PCI 
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(ClinicalTrials.gov: NCT01830543) and RE-DUAL PCI (ClinicalTrials.gov: NCT02164864).
10, 
11
  In the PIONEER AF-PCI trial, the primary safety endpoint was the occurrence of clinically 
significant bleeding (a composite of major bleeding, minor bleeding, or bleeding requiring 
medical attention according to the Thrombolysis in Myocardial Infarction [TIMI] criteria) and 
the secondary efficacy endpoint was the occurrence of a major adverse cardiovascular event (a 
composite of death from cardiovascular causes, myocardial infarction, or stroke).  In the RE-
DUAL PCI trial, the primary safety endpoint was major or clinically relevant nonmajor bleeding 
event as defined by International Society on Thrombosis and Haemostasis (ISTH) and the 
secondary efficacy endpoint was a composite of thromboembolic events (myocardial infarction, 
stroke, or systemic embolism), death, or unplanned revascularization.  For the purpose of 
homogeneity in study endpoints, the present study selected ISTH major or clinically relevant 
nonmajor bleeding as the safety endpoint as used in the RE-DUAL PCI trial, and the composite 
of thromboembolic event, death, or urgent revascularization as the efficacy endpoint, again as 
used in the RE-DUAL PCI trial.  The frequencies of safety and efficacy events were extracted 
from secondary analysis of the PIONEER AF-PCI trial and published results of the RE-DUAL 
trial.
10, 11
 
 
Study Interventions 
 In the PIONEER AF-PCI trial, 2124 patients were randomly assigned to: 1) rivaroxaban 
15 mg once daily + P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel for 12 months); 2) 
rivaroxaban 2.5 mg twice daily + P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel for 1, 6, or 
12 months) + aspirin; and 3) dose-adjusted VKA + P2Y12 inhibitor (clopidogrel, ticagrelor, or 
prasugrel for 1, 6, or 12 months) + aspirin.  In the RE-DUAL PCI trial, 2725 patients were 
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randomized to (1) dabigatran 110 mg twice daily + P2Y12 inhibitor (clopidogrel or ticagrelor for 
12 months); (2) dabigatran 150 mg twice daily + P2Y12 inhibitor (clopidogrel or ticagrelor for 12 
months); and 3) dose-adjusted VKA + P2Y12 inhibitor (clopidogrel or ticagrelor for 12 months) 
+ aspirin (for 1 to 3 months).  To compare the safety and efficacy of NOAC-based regimens 
across the studies, VKA-based triple therapy (VKA plus background dual antiplatelet therapy) 
was selected as the control group.  Similarly, the treatment effect of rivaroxaban-based regimen 
and dabigatran-based regimen were compared with VKA-based triple therapy.  An additional 
comparison was made between reduced-dose NOAC-based regimen (combination of rivaroxaban 
15 mg once daily regimen and dabigatran 110 mg twice daily regimen) and VKA-based triple 
therapy. 
 
Statistical Analysis 
 The non-inferiority hypothesis for the efficacy was tested in the PIONEER AF-PCI trial 
to compare the effect of rivaroxaban dosing strategies with VKA on the composite of 
thromboembolic events, death, or urgent revascularization (Table 1).  The upper boundaries of 
95% confidence interval of relative risk for rivaroxaban dosing strategies were less than 1.38 (the 
non-inferiority margin used in the RE-DUAL PCI trial).  Again, to maintain consistency in the 
bleeding endpoint, the same bleeding definition used in RE-DUAL PCI trial (ISTH major or 
clinically relevant non-major bleeding) was applied to both studies. 
 Detailed methodology of the bivariate analysis has been described previously by 
Kittelson et al.
12, 14
  In brief, risk differences in safety (RDS) and efficacy (RDE) were calculated 
by subtracting the event rate of the control group from the event rate of the treatment groups.  A 
structured two-dimensional plane was thus defined by RDS and RDE, with the lower left quadrant 
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representing reduction in both safety endpoint (major or clinically relevant nonmajor bleeding) 
and efficacy endpoint (thromboembolic event, death, or urgent revascularization).  The 95% 
Wald confidence intervals of RDS and RDE were reported in Table 2 and summarized as a 
rectangle on the plane in Figure 1. 
 Clinically important risk difference was set at 15% to approximate the maximum effect 
size among the four NOAC-based regimens (Table 2).  The non-inferiority margin was set at 
1.38 in accordance with the methods recommended by the Food and Drug Administration for the 
evaluation of NOAC in stroke prevention.
15
  Consequently, in the present analysis, the 
acceptable threshold for excessive risk difference (NIS and NIE) was set at 5.7% (i.e., the rate of 
safety or efficacy outcome in the treatment group cannot exceed that in the control group by 
more than 5.7% when the maximum effect size is reached).  Derivation of the NCB curve is 
provided in the Supplementary Material.
12, 14
 
 The NCB curve divided the risk-benefit plane into two regions: lack-of-benefit region vs. 
benefit region (Figure 1).  The lack-of-benefit region was defined as the partition above the curve.  
The risk-benefit profile was deemed favorable against the control group if the 95% CI rectangle 
did not contain the lack-of-benefit region.  Furthermore, bivariate outcomes were quantitatively 
assessed by the minimum distance from the NCB curve to three reference points: 1) center of the 
rectangle, representing the point estimate of the bivariate outcome; 2) southwest corner of the 
rectangle, representing the lower boundary of the bivariate outcome; and 3) northeast corner of 
the rectangle, representing the upper boundary of the bivariate outcome.  Accordingly, the 
collective treatment effect on safety and efficacy was presented as a point estimate along with a 
range of of bivariate risk difference.  Although their technical statistical properties are different, 
these metrics are analogous to reporting the point estimate with 95% confidence interval; that is, 
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positive values indicate increased risk and negative values indicate decreased risk.  Finally, a 
sensitivity analysis was performed to test a spectrum of non-inferiority margins, ranging from a 
more stringent margin of 1.14 (used in the ENCHANTED trial for evaluating the impact of 
thrombolysis on death or disability
16
) to a less stringent margin of 1.35. 
 The work was supported by research grants from Janssen Scientific Affairs and Bayer, 
the sponsors of the study.  The authors are solely responsible for the design and conduct of this 
study, all study analyses, the drafting and editing of the paper and its final contents. 
 
RESULTS 
Summary of Trial Results 
 Non-inferiority in efficacy and superiority in bleeding were first assessed separately 
(Table 1 and Table 2).  The rivaroxaban-based regimens and the dabigatran 150 mg twice daily 
regimen were non-inferior to VKA triple therapy with respect to the RE-DUAL efficacy 
endpoint (Table 1).  The superiority of rivaroxaban-based or dabigatran-based therapy over VKA 
with respect to bleeding has been demonstrated previously (Table 2).
10, 11
 
 
Qualitative Assessment of the Bivariate Outcome 
 While the above analyses evaluate safety and efficacy separately, a bivariate analysis was 
performed to assess safety and efficacy simultaneously.  Results of four antithrombotic regimens 
were expressed as a rectangle defined by the 95% confidence interval of risk difference in safety 
and efficacy on the risk-benefit plane (Figure 2).  The 0.00% vertical line and 0.00% horizontal 
line represented the superiority boundary for safety and efficacy, respectively.  The rectangles 
for all four NOAC-based regimens were on the left to the vertical line, indicating that these 
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regimens achieved superiority in bleeding compared with VKA.  The four rectangles crossed the 
horizontal line, indicating that superiority in efficacy was not achieved.  Similarly, rivaroxaban-
based regimen, dabigatran-based regimen, and reduced dosing strategy were superior in safety 
when compared with VKA-based triple therapy (Figure 3 and Figure 4). 
 The NCB curve was derived using a non-inferiority margin of 1.38 (corresponding to an 
acceptable threshold for excessive risk difference of 5.7%) and divided the plane into two 
regions.  The rectangles of the four NOAC-based regimens did not contain the partition above 
the curve (lack-of-benefit region), indicating that these regimens were favorable over VKA 
(Figure 2).  Similar risk-benefit profiles were observed in rivaroxaban- or dabigatran-based 
regimen as well as reduced-dose regimen (Figure 3 and Figure 4).  Analysis of the pooled data 
suggested that NOAC-based regimen was superior in safety and non-inferior in efficacy (Figure 
5). 
 
Quantitative Assessment of the Bivariate Outcome 
 Quantitatively, bivariate outcomes were assessed by the minimum distance from the NCB 
curve to the center (point estimate) and opposing corners of the rectangle (upper and lower 
boundaries).  The effect size in terms of bivariate outcome was then summarized in the forest 
plot (Figure 6).  Rivaroxaban 15 mg once daily and 2.5 mg twice daily were associated with a 
bivariate risk reduction of 5.6% (2.3%–8.8%) and 5.5% (2.1%–8.8%) respectively, and 
dabigatran 110 mg twice daily and 150 mg twice daily reduced the risk by 3.8% (0.5%–7.0%) 
and 6.3% (2.4%–9.8%) respectively.  Both the combined 2.5 mg and 15 mg rivaroxaban-based 
and the combined 110 mg and 150 mg dabigatran-based regimens were favorable over VKA, 
with a bivariate risk reduction of 5.6% (3.2%–7.8%) and 4.9% (2.5%–7.3%), respectively.  The 
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reduced-dose regimens of 15 mg Rivaroxaban and 110 mg Dabigatran and all 4 NOAC-based 
regimens combined demonstrated comparable bivariate risk reductions over VKA of 4.5% 
(2.2%–6.8%) and 5.5% (3.4%–7.5%), respectively (Figure 6). 
 
Sensitivity Analysis of the Non-Inferiority Margin 
 In the sensitivity analysis, a spectrum of non-inferiority margin (i.e., 1.14, 1.20, 1.25, 
1.30, and 1.35) was used to test the robustness of treatment effects of NOAC-based regimens 
(Figure S1 to Figure S5).  Rivaroxaban 15 mg daily and rivaroxaban 2.5 mg twice daily maintain 
an advantage over VKA when the non-inferiority margin is set at 1.25.  Dabigatran 110 mg twice 
daily and dabigatran 150 mg twice daily maintained an advantage over VKA when the margin 
was set at 1.35 and 1.20, respectively.  When all 4 regimens were taken together, the NOAC-
based regimens showed a favorable profile at the non-inferiority bound of 1.14.  In other words, 
if a 2.1% threshold of risk difference is clinically acceptable, NOAC would be preferred over 
VKA in the bivariate model that weighs thromboembolism, death, and urgent revascularization 
against bleeding risks. 
 
DISCUSSION 
 Clinicians must consider bleeding and ischemic outcomes simultaneously when making a 
decision regarding antithrombotic management in AF patients undergoing stent placement.  The 
superiority of rivaroxaban-based or dabigatran-based therapy over VKA based strategies with 
respect to bleeding has been demonstrated previously.
10, 11
  If a regimen is safer, then with 
respect to efficacy, non-inferiority instead of superiority is a reasonable goal.  The advantage of a 
bivariate analysis is that it potentially allows one to evaluate if whether a regimen is superior in 
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safety and simultaneously non-inferior in efficacy yielding an overall net clinical benefit.
13, 14
  
The efficacy endpoint in RE-DUAL was used for the non-inferiority analysis as it was broader 
and yielded more events than the narrower endpoint used in the PIONEER study (i.e., 
myocardial infarction, stroke, and cardiovascular death).  When weighed against the same scale 
of bleeding risk, both rivaroxaban-based and dabigatran-based regimens were favorable over a 
VKA-based regimen.  Using the efficacy endpoint from the RE-DUAL trial, the rivaroxaban 
regimens also achieve non-inferiority when analyzed as the sole endpoint independent of safety 
using traditional statistical methods.  Results from the PIONEER AF-PCI trial and RE-DUAL 
PCI trial both demonstrate that NOAC-based anticoagulation plus background antiplatelet 
therapy can be a desirable alternative to VKA-based triple therapy. 
 One simple approach to assess net clinical benefit (NCB) is to subtract the event rate of 
safety outcome from the rate of efficacy outcome.  The linear function of this conventional 
approaches treats the tradeoff as symmetrical and unlimited.  Thus, a substantial increase in 
bleeding would be inappropriately deemed acceptable given a corresponding reduction in 
thromboembolism.  A more sophisticated approach, however, is to calculate NCB in a bivariate 
model which is a novel statistical method devised to characterize the non-linear nature of 
tradeoffs in a two-dimensional outcome.
13, 14
  The bivariate model is a weighted aggregate of risk 
difference determined by the relative impact of treatment on safety versus efficacy.
17
  The output 
includes a qualitative display on the safety-efficacy plane and a quantitative comparison of the 
risk difference as the bivariate outcome.  The bivariate approach has been utilized to compare the 
risk-benefit profile of anticoagulation and antihypertensive strategies and to devise the stopping 
criteria for the interim analysis.
14, 18-20
  Furthermore, in the Kids-DOTT trial (ClinicalTrials.gov 
Identifier: NCT00687882), the bivariate endpoint was utilized as the primary outcome measure 
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to gauge the tradeoff between the risks of recurrent venous thromboembolism and bleeding 
associated with shortened-duration vs. conventional-duration anticoagulation.  This approach 
could be a valuable addition to the conventional tools to evaluate the risk-benefit balance of 
treatment. 
 As in the interpretation of unidimensional outcome, inference derived from the bivariate 
model may be affected by the choice of non-inferiority margin.  There are no historical data to 
guide the determination of non-inferiority margin for the endpoint of bleeding and 
thromboembolic events in the population of AF with stent placement.  This study adopts the non-
inferiority margin of 1.38, as recommended by the regulatory agency for NOAC trials in the 
assessment of stroke prevention,
15
 which has been considered as the most clinically relevant 
available reference.
21
  Thus far there is no consensus on the best practice for simultaneously 
analyzing multiple disparate endpoints to appraise the net clinical benefit of antithrombotic 
regimens.
22, 23
  Nevertheless, results from the present analysis inform future trials regarding the 
extent of excessive thromboembolic risks that may be considered acceptable provided the 
substantial benefits in bleeding reduction with NOAC-based regimens. 
 
LIMITATIONS 
 The present analysis evaluates the tradeoff between the primary safety endpoint (clinical 
significant bleeding) and the primary efficacy endpoint (thromboembolism, death, and urgent 
revascularization) which presumably have comparable clinical impact.  Patient values and 
preferences were not considered when assessing the risk-benefit of antithrombotic regimens.  
The tradeoff between the components of the safety and efficacy composite endpoints (for 
instance, TIMI major bleeding versus myocardial infarction) was not assessed although it may 
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also be of clinical interest.  It is also noteworthy that the present analysis did not account for 
multiple or recurrent events.  In addition, study-level data instead of individual-level data were 
analyzed in the bivariate model without accounting for potential between-study variance in 
treatment effects.  Furthermore, both included trials were powered for the bleeding endpoint 
rather than the quantified bivariate outcome in this analysis.  Finally, only 12% and 9% of the 
PIONEER and RE-DUAL study participants presented with STEMI and had primary PCI as the 
index event.  More data are required to confirm the net clinical benefit of NOAC-based regimen 
in this subset. 
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CONCLUSIONS 
 In the management of AF patients who received coronary stenting, both rivaroxaban-
based and dabigatran-based regimens were favorable over VKA plus dual antiplatelet therapy in 
a bivariate analysis that weighs thromboembolism, death, and urgent revascularization against 
bleeding risks. 
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Legends of Figures 
 
Figure 1. Interpretation of the bivariate analysis.  Qualitatively, a favorable net clinical benefit is 
established if the rectangle defined by 95% confidence interval of risk difference does not 
include the lack-of-benefit region.  Quantitatively, the bivariate outcome is measured by the 
minimum distance from the curve to the center (point estimate), southwest corner (lower bound), 
and northeast corner (upper bound) of the rectangle. 
 
Figure 2. Bivariate analysis of four antithrombotic regimens. 
 
Figure 3. Bivariate analysis of rivaroxaban-based and dabigatran-based regimens 
 
Figure 4. Bivariate analysis of reduced-dose (rivaroxaban 15 mg daily or dabigatran 110 mg 
twice daily) regimen 
 
Figure 5. Bivariate analysis of all NOAC-based regimens 
 
Figure 6. Comparison of bivariate outcome among antithrombotic regimens 
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Table 1. The composite efficacy endpoint of thromboembolic event, death, and urgent revascularization in the 
PIONEER AF-PCI and RE-DUAL PCI trial 
*
 
 
Antithrombotic Regimen 
Treatment 
n/N (%) 
VKA 
n/N (%) 
Relative Risk 
(95% CI) 
P-value 
for Non-
Inferiorit
y PIONEER AF-PCI     
Rivaroxaban 15 mg once daily + P2Y12 inhibitor 63/694 (9.08) 64/695 (9.21) 0.99 (0.71 to 
1.37) 
0.0234 
Rivaroxaban 2.5 mg twice daily + P2Y12 inhibitor + 
aspirin 
64/704 (9.09) 64/695 (9.21) 0.99 (0.71 to 
1.37) 
0.0234 
Rivaroxaban (combined) 127/1398 (9.08) 64/695 (9.21) 0.99 (0.74 to 
1.31) 
0.0108 
RE-DUAL PCI     
Dabigatran 110 mg twice daily + P2Y12 inhibitor 149/981 (15.19) 131/981 
(13.35) 
1.14 (0.92 to 
1.41) 
0.0407 
Dabigatran 150 mg twice daily + P2Y12 inhibitor 90/763 (11.80) 98/764 (12.83) 0.92 (0.70 to 
1.20) 
0.0015 
Dabigatran (combined) 239/1744 
(13.70) 
131/981 
(13.35) 
1.03 (0.84 to 
1.25) 
0.0017 
 
* 
P-value for non-inferiority was calculated at the one-sided alpha level of 0.025 with upper confidence limit of 1.38. 
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Table 2. Safety and efficacy of antithrombotic regimens in the PIONEER AF-PCI and RE-DUAL PCI trial 
*
 
 
Antithrombotic Regimen 
Treatment 
n/N (%) 
Control 
n/N (%) 
Risk Difference 
% (95% CI) 
P-value 
for 
Superiority 
Safety endpoint: ISTH major or clinically relevant nonmajor bleeding 
PIONEER AF-PCI     
Rivaroxaban 15 mg once daily + P2Y12 inhibitor 
(Regimen 1) 
110/696 
(15.80) 
170/697 
(24.39) 
-8.59 (-12.77 to -
4.40) 
<0.0001 
Rivaroxaban 2.5 mg twice daily + P2Y12 inhibitor + 
aspirin (Regimen 2) 
119/706 
(16.86) 
170/697 
(24.39) 
-7.53 (-11.75 to -
3.32) 
0.0005 
Rivaroxaban-based regimen (Regimen 1 + 2) 229/1402 
(16.33) 
170/697 
(24.39) 
-8.06 (-11.79 to -
4.33) 
<0.0001 
RE-DUAL PCI     
Dabigatran 110 mg twice daily + P2Y12 inhibitor 
(Regimen 3) 
151/981 
(15.39) 
264/981 
(26.91) 
-11.52 (-15.10 to -
7.94) 
<0.0001 
Dabigatran 150 mg twice daily + P2Y12 inhibitor 
(Regimen 4) 
154/763 
(20.18) 
196/764 
(25.65) 
-5.47 (-9.68 to -
1.26) 
0.0110 
Dabigatran-based regimen (Regimen 3 + 4) 305/1744 
(17.49) 
264/981 
(26.91) 
-9.42 (-12.72 to -
6.12) 
<0.0001 
Reduced-dose NOAC-based regimen (Regimen 1 + 3) 261/1677 
(15.56) 
434/1678 
(25.86) 
-10.30 (-13.02 to -
7.58) 
<0.0001 
NOAC-based regimen (Regimen 1 + 2 + 3 + 4) 534/3146 
(16.97) 
434/1678 
(25.86) 
-8.89 (-11.36 to -
6.42) 
<0.0001 
Efficacy endpoint: thromboembolic event, death, or urgent revascularization 
PIONEER AF-PCI     
Rivaroxaban 15 mg once daily + P2Y12 inhibitor 
(Regimen 1) 
63/694 (9.08) 64/695 (9.21) -0.13 (-3.16 to 
2.90) 
0.93 
Rivaroxaban 2.5 mg twice daily + P2Y12 inhibitor + 
aspirin (Regimen 2) 
64/704 (9.09) 64/695 (9.21) -0.12 (-3.14 to 
2.90) 
0.94 
Rivaroxaban-based regimen (Regimen 1 + 2) 127/1398 
(9.08) 
64/695 (9.21) -0.12 (-2.75 to 
2.50) 
0.93 
RE-DUAL PCI     
Dabigatran 110 mg twice daily + P2Y12 inhibitor 
(Regimen 3) 
149/981 
(15.19) 
131/981 
(13.35) 
1.83 (-1.26 to 
4.93) 
0.25 
Dabigatran 150 mg twice daily + P2Y12 inhibitor 
(Regimen 4) 
90/763 
(11.80) 
98/764 
(12.83) 
-1.03 (-4.33 to 
2.26) 
0.54 
Dabigatran-based regimen (Regimen 3 + 4) 239/1744 
(13.70) 
131/981 
(13.35) 
0.35 (-2.32 to 
3.02) 
0.80 
Reduced-dose NOAC-based regimen (Regimen 1 + 3) 212/1675 
(12.66) 
195/1676 
(11.63) 
1.02 (-1.19 to 
3.23) 
0.37 
NOAC-based regimen (Regimen 1 + 2 + 3 + 4) 366/3142 
(11.65) 
195/1676 
(11.63) 
0.01 (-1.89 to 
1.92) 
0.99 
 
*
 All 95% confidence intervals of the risk differences exclude the non-inferiority margin of +5.7% 
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